Introduction: Although the prognosis of pediatric acute myeloid leukemia (pAML) has
improved, with current survival rates up to 75%, relapse rates remain high. Areas covered …

Although acute myelogenous leukemia (AML) accounts for< 20% of leukemia in children, it
is responsible for over half of all pediatric leukemia deaths. Improvement in event-free …

Pediatric acute myeloid leukemia (AML) is currently associated with survival rates as high as
70%. However, many events still occur, side effects are significant, and late effects occur and …

Prognosis of childhood acute myeloid leukemia (AML) has improved significantly over the
past decades, from nearly no child surviving to a present probability of cure of approximately …

Pediatric acute myeloid leukemias (AMLs) are a heterogeneous group of diseases that can
be classified based on morphology, lineage, and genetics. Recent improvements in the …

Approximately two-thirds of children with acute myeloid leukemia (AML) are cured with
intensive multi-agent chemotherapy. However, refractory and relapsed AML remains a …

Further incorporation of genomic and molecular data in pediatric AML will allow for
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …

The outcome for children with acute myeloid leukemia (AML) has improved significantly over
the past 30 years, with complete remission and overall survival rates exceeding 90 and …

Childhood acute myeloid leukemia is rare, but accounts for a significant number of
malignancy-related deaths in this age group. However, the prognosis has improved over …

Acute myeloid leukemia is a heterogeneous disease that accounts for approximately 20% of
acute leukemias in children and adolescents. Despite the lack of targeted therapy for most …